Samuel Hall focuses on EU competition law as well as EU regulatory law. Before joining Van Bael & Bellis, Samuel worked in the Brussels and London offices of a well-known international law firm advising mainly on EU and UK competition law issues, gaining particular experience in the pharmaceuticals sector. During his time as a trainee in London, Samuel also gained valuable experience of pharmaceutical patent litigation. Samuel has also worked as a research assistant at the University of Sheffield.
13
On 9 September 2020, Advocate General (“AG”) Saugmandsgaard Øe issued his opinion in Deutsche Telekom v. European Commission (Case C-152/19) and Slovak Telekom v. European Commission (Case C-165/19) advising the Court of Justice (“ECJ”) to dismiss the parties’ challenges to the Commission’s finding (...)
16
Background On 9 September 2020, the French Competition Authority (the “FCA”) imposed a fine of € 444 million on Genentech, Novartis and Roche for abusing their collective dominant position on the market for the commercialisation of drugs for the treatment of age-related macular degeneration (AMD) (...)
19 avenue Jean Aicard
75011 Paris, France
106 West 32nd Street, Suite 144
New York, NY, 10001, USA
61-63 Rochester Place
NW1 9JU London, UK
